Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Los Angeles Capital Management & Equity Research Inc.

Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 793.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 77,226 shares of the biopharmaceutical company’s stock after purchasing an additional 68,579 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Alexion Pharmaceuticals were worth $10,834,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of ALXN. Dimensional Fund Advisors LP increased its position in shares of Alexion Pharmaceuticals by 4.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 321,459 shares of the biopharmaceutical company’s stock valued at $38,975,000 after purchasing an additional 13,679 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in shares of Alexion Pharmaceuticals by 0.9% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 23,624 shares of the biopharmaceutical company’s stock worth $2,874,000 after acquiring an additional 200 shares during the last quarter. LS Investment Advisors LLC grew its holdings in shares of Alexion Pharmaceuticals by 6.6% in the 2nd quarter. LS Investment Advisors LLC now owns 6,533 shares of the biopharmaceutical company’s stock worth $795,000 after acquiring an additional 402 shares during the last quarter. Peregrine Capital Management LLC grew its holdings in shares of Alexion Pharmaceuticals by 24.9% in the 2nd quarter. Peregrine Capital Management LLC now owns 97,420 shares of the biopharmaceutical company’s stock worth $11,853,000 after acquiring an additional 19,427 shares during the last quarter. Finally, Gradient Investments LLC grew its holdings in shares of Alexion Pharmaceuticals by 8.0% in the 2nd quarter. Gradient Investments LLC now owns 2,555 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 189 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

ALXN has been the topic of a number of recent research reports. TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price on the stock in a report on Tuesday, October 31st. Oppenheimer Holdings, Inc. upgraded Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 target price on the stock in a report on Friday, July 28th. Royal Bank Of Canada initiated coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 target price on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $153.00 target price (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $154.01.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $110.87 on Friday. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The firm has a market capitalization of $24,650.00, a PE ratio of 22.49, a price-to-earnings-growth ratio of 1.20 and a beta of 1.22. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Los Angeles Capital Management & Equity Research Inc.” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2017/11/18/alexion-pharmaceuticals-inc-alxn-shares-bought-by-los-angeles-capital-management-equity-research-inc.html.

In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders sold 16,490 shares of company stock valued at $2,337,251 in the last ninety days. Insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply